Mid-Day Market Update: Dow Jumps 100 Points; Spero Therapeutics Shares Plunge
U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 100 points on Tuesday. The Dow traded up 0.35% to 33,178.65 while the NASDAQ rose 0.01% to 12,537.98. The SP also rose, gaining, 0.54% to 4,177.90. Also check this: Executives Buy Around $1.6M Of 4 Penny Stocks Leading and Lagging Sectors Energy shares climbed 2.5% on Tuesday. Meanwhile, top gainers in the sector included VOC Energy Trust (NYSE: TTI ), up 16% and CVR Energy, Inc. (NYSE: CVI ) up 13%. In trading on Tuesday, consumer discretionary shares fell by 0.2%. Top Headline Pfizer Inc. (NYSE: PFE ) posted upbeat results for its first quarter on Tuesday. Pfizer posted quarterly adjusted earnings of $1.62 per share, exceeding analysts’ estimates of $1.50 per share. The company’s quarterly sales came in at $25.70 billion, versus expectations of $23.95 billion. Pfizer revised its FY22 adjusted EPS guidance to $6.25-$6.45 to reflect $0.11 negative impact for accounting policy change. The company also sees sales of $98 billion to $102 billion.
Mid-Day Market Update: Dow Jumps 100 Points; Spero Therapeutics Shares Plunge
U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 100 points on Tuesday. The Dow traded up 0.35% to 33,178.65 while the NASDAQ rose 0.01% to 12,537.98. The SP also rose, gaining, 0.54% to 4,177.90. Also check this: Executives Buy Around $1.6M Of 4 Penny Stocks Leading and Lagging Sectors Energy shares climbed 2.5% on Tuesday. Meanwhile, top gainers in the sector included VOC Energy Trust (NYSE: TTI ), up 16% and CVR Energy, Inc. (NYSE: CVI ) up 13%. In trading on Tuesday, consumer discretionary shares fell by 0.2%. Top Headline Pfizer Inc. (NYSE: PFE ) posted upbeat results for its first quarter on Tuesday. Pfizer posted quarterly adjusted earnings of $1.62 per share, exceeding analysts’ estimates of $1.50 per share. The company’s quarterly sales came in at $25.70 billion, versus expectations of $23.95 billion. Pfizer revised its FY22 adjusted EPS guidance to $6.25-$6.45 to reflect $0.11 negative impact for accounting policy change. The company also sees sales of $98 billion to $102 billion.